Citius Pharmaceuticals, Inc. ('Citius') (Nasdaq: CTXR), a late-stage biopharmaceutical company, announced on Friday that it has chosen Biorasi, LLC ('Biorasi'), a global clinical research organisation, to support the expansion of the firm's Phase three Mino-Lok trial to additional sites outside of the United States.
If Mino-Lok (MLT) is approved then it would be the first-and-only antibiotic lock solution FDA-approved to salvage infected central venous catheters (CVCs) causing catheter-related blood stream infections (CRBSIs).
The Mino-Lok Phase 3 pivotal superiority trial (NCT02901717), a multi-centre, randomised, open-label, blinded study, is to study the efficacy and safety of MLT, a novel antibiotic lock therapy that combines minocycline with edetate disodium. During the study, subjects will receive one MLT dose daily with a dwell time of two to four hours for a total of seven doses. The investigator for subjects in the Control arm will determine the antibiotic used in the lock, dose, dwell time, and number of days of administration based on institutional standards or Infectious Diseases Society of America (IDSA) guidelines.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT